Tigecycline therapy for carbapenem‐resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. (12th December 2014)

• Record Type: Journal Article
• Authors: van Duin, D.; Cober, E. D.; Richter, S. S.; Perez, F.; Cline, M.; Kaye, K. S.; Kalayjian, R. C.; Salata, R. A.; Evans, S. R.; Fowler, V. G.; Bonomo, R. A.; Cantón, R.
• Is Part Of: Clinical microbiology and infection. Volume 20:Number 12(2014:Dec.)
• Page Start: O1117
• Page End: O1120
• Publication Date: 2014-12-12
• Subjects: Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1111/1469-0691.12714
• Languages: English
• ISSNs: 1198-743X

Abstract

<abstract abstract-type="main" id="clm12714-abs-0001"> <title>Abstract</title> <p>Carbapenem‐resistant <italic>Klebsiella pneumoniae</italic> (CRKP) is an increasing global threat. Here, we describe the prevalence and impact of tigecycline use in a cohort of patients with CRKP bacteriuria nested within a multicentre, prospective study. In the 21‐month study period, 260 unique patients were included. Tigecycline was given to 80 (31%) patients. The use of tigecycline during the index hospitalization was significantly associated with the subsequent development of tigecycline resistance in the same patient (OR, 6.13; 95% CI, 1.15–48.65; p 0.03). In conclusion, the use of tigecycline with CRKP bacteriuria is common, and is associated with the subsequent development of tigecycline resistance.</p> </abstract>